---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-006847"
form_type: "8-K"
ticker: "CMPX"
cik: "0001738021"
company_name: "Compass Therapeutics, Inc."
filed_at: "2024-12-10T23:59:59+00:00"
generated_at: "2026-05-29T05:13:37.415628+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Compass Therapeutics appoints Barry Shin as CFO; Neil Lerner as PAO

## Summary
- Barry Shin named CFO effective Dec 9, 2024; base salary $475K, target bonus 45%, sign-on $50K, and equity grants of 800K shares total.
- Neil Lerner appointed principal accounting officer; he was VP of Finance since November 2020.
- Shin replaces Thomas Schuetz as principal financial officer; Schuetz remains CEO.
- Press release highlights 2025 catalysts: topline data for CTX-009 expected in Q1 2025.
- Shin previously served as CFO/COO at Trevena and held investment banking roles at Mizuho, Guggenheim, and Piper Sandler.

## SEC filing metadata
- accession: 0001171843-24-006847
- form_type: 8-K
- ticker: CMPX
- cik: 0001738021
- company_name: Compass Therapeutics, Inc.
- filed_at: 2024-12-10T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1738021/000117184324006847/0001171843-24-006847-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1738021/000117184324006847/f8k_121024.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-006847
- JSON: https://secwatch.observer/filing/0001171843-24-006847.json
- Plain text: https://secwatch.observer/filing/0001171843-24-006847.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.